TGFB1 and cancer: In addition, isoform-selective inhibitors are also identified and selected for clinical evaluation, with the rational that that selectively targeting the cancer-relevant TGF-β pathway may avoid the side effects of broad TGF-β inhibition and benefit most from the TGF-β targeting.